首页> 外文期刊>Transplantation Proceedings >Human cytomegalovirus (CMV) UL97 D605E mutation has a higher prevalence in infants with primary CMV infection compared with transplant recipients with CMV recurrence
【24h】

Human cytomegalovirus (CMV) UL97 D605E mutation has a higher prevalence in infants with primary CMV infection compared with transplant recipients with CMV recurrence

机译:与巨细胞病毒复发的移植接受者相比,人巨细胞病毒(CMV)UL97 D605E突变在原发性巨细胞病毒感染婴儿中的患病率更高

获取原文
获取原文并翻译 | 示例
           

摘要

Mutations in the UL97 gene are a major mechanism of human cytomegalovirus (CMV) resistance to gancyclovir (GCV). Some mutations may show different regional distributions. To analyze UL97 mutations in Chinese people, we scanned the UL97 gene fragment among virus isolates from 27 infants as well as blood samples from 28 solid organ transplant (SOT) and 42 bone marrow transplant (BMT) recipients with active CMV infections as defined by DNAemia or PP65 antigenemia. Only a known GCV-resistant mutation M406V was found in a BMT recipient. However, the D605E mutation was identified in 18 of 27 (66.7%) infants as well as 11 of 28 (39.3%) SOT and 17 of 42 (40.5%) BMT recipients. It was significantly different between the infants and transplant recipients (P <.05). So far, the influence of D605E mutation on GCV-resistance is controversial. In this study, 18 D605E mutants, 9 wild type (WT) isolates, and AD169 controls cultured in fibroblasts were tested for phenotypic drug resistance using a plaque reduction assay. The dose of GCV required for 50% inhibition of plaque formation (IC50) was 1.20 ± 0.67 μmol/L (D605E), 1.71 ± 0.64 μmol/L (WT), and 1.43 ± 0.70 μmol/L (AD169), respectively. This small difference could be caused by analytical error. We concluded that the UL97 D605E mutation showed a different prevalence between infants with primary CMV infection and transplant recipients with CMV recurrence. However, it was not related to a resistant phenotype to GCV.
机译:UL97基因的突变是人类巨细胞病毒(CMV)对更昔洛韦(GCV)的抗性的主要机制。一些突变可能显示不同的区域分布。为了分析中国人的UL97突变,我们对DNA定义为活动性CMV感染的27例婴儿的病毒分离株以及28例实体CMV感染的28例实体器官移植(SOT)和42例骨髓移植(BMT)的血液样本中的UL97基因片段进行了扫描。或PP65抗原血症。在BMT受体中仅发现了一个已知的抗GCV的突变M406V。但是,在27名(66.7%)婴儿中有18名以及在28名(39.3%)SOT中有11名和42名(40.5%)BMT接受者中发现了D605E突变。婴儿和移植受者之间存在显着差异(P <.05)。到目前为止,D605E突变对GCV耐药性的影响尚存争议。在这项研究中,使用噬斑减少试验测试了在成纤维细胞中培养的18个D605E突变体,9个野生型(WT)分离株和AD169对照的表型耐药性。抑制斑块形成(IC50)50%所需的GCV剂量分别为1.20±0.67μmol/ L(D605E),1.71±0.64μmol/ L(WT)和1.43±0.70μmol/ L(AD169)。这种微小差异可能是由分析误差引起的。我们得出的结论是,UL97 D605E突变在原发性CMV感染婴儿和CMV复发的移植接受者之间显示出不同的患病率。但是,它与对GCV的耐药表型无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号